Loading people...
David Rubin is a Managing Director at the Merck Global Health Innovation Fund, based in the Greater New York City Area. In this role, he leads investments out of a $500 million evergreen venture vehicle, targeting early-stage digital health, healthcare IT, and life sciences technology companies. He actively manages portfolio assets and serves on the board of directors for several clinical-tech startups, including Clinical Ink and SubjectWell. Prior to his decade-long tenure within the venture and corporate divisions of Merck & Co., he held a position at the venture-backed international firm Cognia Corporation. Throughout his career, he has developed deep domain expertise in scaling early-stage biotechnology enterprises. His professional background centers on corporate strategy and venture capital execution, with a current focus on funding scalable innovations that improve clinical trials, data analytics, and healthcare delivery.
David Rubin is a distinguished Managing Director at the Merck Global Health Innovation Fund (MGHIF), a strategic corporate venture fund dedicated to identifying and nurturing groundbreaking companies that are reshaping the future of healthcare. At MGHIF, David plays a pivotal role in sourcing, evaluating, and executing investments in early to growth stage companies that align with Merck's broader mission to improve global health.
His primary investment focus areas at MGHIF are diverse yet strategically aligned with the evolving healthcare landscape. These include digital health solutions, such as remote patient monitoring, telehealth platforms, and digital therapeutics designed to empower patients and providers. He also targets companies leveraging advanced data analytics, artificial intelligence, and machine learning to derive actionable insights from complex health data, thereby enhancing diagnostics, treatment pathways, and drug discovery processes. Furthermore, David is interested in innovations that improve healthcare delivery models, patient engagement, and real world evidence generation.
David's career background typically reflects a deep understanding of both the healthcare industry and venture capital. Professionals in his position often bring a wealth of experience from roles in corporate development, strategic consulting, or other investment firms, coupled with a strong foundation in life sciences or finance. This multidisciplinary expertise enables him to identify promising technologies and business models that have the potential for significant impact within the complex healthcare ecosystem. His leadership helps guide portfolio companies through critical growth stages, leveraging Merck's extensive resources and industry insights.
While specific individual investments for David Rubin are often proprietary, the Merck Global Health Innovation Fund has a track record of investing in companies that are at the forefront of healthcare innovation. These investments typically span areas like oncology support platforms, solutions for chronic disease management, and tools that enhance clinical trial efficiency. David's contributions are instrumental in expanding MGHIF's portfolio with companies poised to deliver transformative value to patients and healthcare systems worldwide, reinforcing Merck's commitment to innovation beyond traditional pharmaceuticals. His work ensures that MGHIF remains a key player in driving the next generation of health technology advancements.
David Rubin is a Managing Director at the Merck Global Health Innovation Fund (MGHIF), where he focuses on investing in innovative healthcare technology companies.
David Rubin invests in digital health solutions, data analytics, artificial intelligence in healthcare, and other health technology companies that aim to transform patient care and healthcare delivery.
David Rubin works as a Managing Director at the Merck Global Health Innovation Fund (MGHIF), a corporate venture fund of Merck.
